Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing dopaminergic D2 receptors and/or antagonizing or inhibiting activity of receptors such as the 5-HT2 serotonin receptors using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HTID and/or the 5-HTIB receptor, without agonizing (or very weakly agonising) the 5-HT2B receptor using the compounds and compositions disclosed herein.
